SLC5A2 and acute kidney injury: For example, in a meta-analysis of placebo-controlled trials, allocation to an SGLT2 inhibitor reduced the risk of AKI (defined by its specific Medical Dictionary for Regulatory Activities Preferred Term) by 23% (95% CI 19–26%) [1].